News
Public · Published
Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
Johnson & Johnson announced three clinical analyses for presentation at TCT 2026 about Impella heart-pump support during and after high-risk coronary procedures. Registry data from 1,379 patients in U.S. and European hospitals showed lower in-hospital cardiovascular mortality and lower 30- and 90-day mortality than rates recently reported in CHIP-BCIS3.
Published:
Updated:
What happened
Johnson & Johnson announced three clinical analyses for presentation at TCT 2026 about Impella heart-pump support during and after high-risk coronary procedures. Registry data from 1,379 patients in U.S. and European hospitals showed lower in-hospital cardiovascular mortality and lower 30- and 90-day mortality than rates recently reported in CHIP-BCIS3.
Confirmed
Global impact / market context
If clinicians view the findings as relevant to their patients, Impella use could remain part of care for complex heart procedures, supporting demand for the device. However, the data do not show that the pump alone caused better outcomes, since patient selection, procedure choices, and follow-up care also matter.
Analyst inference
The comparison uses registry records, meaning observations from routine care, rather than a stated direct trial against CHIP-BCIS3. Differences in patients, treatment choices, or care could influence the mortality results, so they provide context but do not establish how much Impella changes outcomes or revenue.
Analyst inference
What to watch
- The TCT presentations could clarify patient selection, outcome measurement, and whether the registry analysis accounts for differences from CHIP-BCIS3, helping assess how comparable the reported mortality figures are. Analyst inference
- Further evidence across patient groups and hospitals could show whether lower reported mortality persists; that would help clinicians judge where Impella support is appropriate and affect device use. Analyst inference
- Johnson & Johnson’s stated focus on patient selection and post-procedure care means clinical protocols, not only the pump, may shape adoption and demand for Impella support. Analyst inference
Evidence
- Original source link unavailable